KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Change in Cash (2018 - 2025)

Historic Change in Cash for Takeda Pharmaceutical (TAK) over the last 8 years, with Q4 2025 value amounting to -$318.3 million.

  • Takeda Pharmaceutical's Change in Cash rose 8752.09% to -$318.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $964.0 million, marking a year-over-year decrease of 2488.97%. This contributed to the annual value of -$402.4 million for FY2025, which is 4306.28% up from last year.
  • Per Takeda Pharmaceutical's latest filing, its Change in Cash stood at -$318.3 million for Q4 2025, which was up 8752.09% from $2.2 billion recorded in Q3 2025.
  • Over the past 5 years, Takeda Pharmaceutical's Change in Cash peaked at $3.1 billion during Q1 2021, and registered a low of -$2.9 billion during Q2 2021.
  • Its 5-year average for Change in Cash is -$29.7 million, with a median of -$202.8 million in 2025.
  • Over the last 5 years, Takeda Pharmaceutical's Change in Cash had its largest YoY gain of 408199.51% in 2024, and its largest YoY loss of 131861.1% in 2024.
  • Over the past 5 years, Takeda Pharmaceutical's Change in Cash (Quarter) stood at $970.5 million in 2021, then tumbled by 175.43% to -$732.0 million in 2022, then skyrocketed by 75.44% to -$179.8 million in 2023, then plummeted by 1318.61% to -$2.6 billion in 2024, then skyrocketed by 87.52% to -$318.3 million in 2025.
  • Its Change in Cash was -$318.3 million in Q4 2025, compared to $2.2 billion in Q3 2025 and -$225.8 million in Q2 2025.